Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVE:
Compare the efficacy and side effects of allopurinol versus glucantime versus
allopurinol/glucantime in patients in Brazil with cutaneous leishmaniasis.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Harvard School of Public Health Harvard School of Public Health (HSPH)